Literature DB >> 7538251

Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.

A Zibert1, E Schreier, M Roggendorf.   

Abstract

It has been postulated that antibodies specific to the hypervariable region 1 (HVR1) within the putative envelop protein E2 of hepatitis C virus (HCV) can neutralize virus. We studied such antibodies in sera of patients who were infected in a single-source outbreak by a contaminated anti-D immunoglobulin preparation (HCV-AD78). The nucleotide sequences of cDNAs encoding HVR1 of HCV-AD78 were determined. The four major variants (HVR1.A, B, C, and D) were expressed as fusion proteins in Escherichia coli. Sixty-seven percent of sera contained antibodies to HVR1.A. Sera unrelated to infection of the outbreak also recognized HVR1.A but to a lesser extent (15%), suggesting that not all HVR1-specific antibodies are absolutely isolate-specific. Antibodies directed against individual variants of HVR1 were found in sera obtained early postinfection (p.i.) (< or = 1 year) but also in sera obtained several years later. An in vitro binding assay of HCV to tissue culture cells was employed to further characterize these sera. Five of seven sera that were obtained early p.i. prevented binding of HCV to cells. Preincubation of such sera with HVR1-specific fusion proteins restored binding of HCV to cells in four of five sera. These findings suggest that the majority of neutralizing antibodies are directed against HVR1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538251     DOI: 10.1006/viro.1995.1196

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  65 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.

Authors:  F Penin; C Combet; G Germanidis; P O Frainais; G Deléage; J M Pawlotsky
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.

Authors:  S C Ray; Q Mao; R E Lanford; S Bassett; O Laeyendecker; Y M Wang; D L Thomas
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Hepatitis C virus infection of human hepatoma cell line 7721 in vitro.

Authors:  Z Q Song; F Hao; F Min; Q Y Ma; G D Liu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

5.  Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.

Authors:  L M Lagging; K Meyer; R J Owens; R Ray
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 6.  Gene vaccination for hepatitis C.

Authors:  G Inchauspé
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 8.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

9.  Evolution of hypervariable region 1 of hepatitis C virus in primary infection.

Authors:  A Manzin; L Solforosi; E Petrelli; G Macarri; G Tosone; M Piazza; M Clementi
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.